This week's signal: the UK MedTech funding gap is real, and the market is moving to close it. Thena Capital's £45 million fund anchored by the British Business Bank is the clearest evidence yet that institutional capital is taking UK medical technology seriously as a standalone thesis. Star51 Capital's inaugural MedTech fund, co-led by Abbott and Mayo Clinic, is a separate but related story about how the capital formation stack for medtech companies is getting more sophisticated. Dexcom clears Stelo for children, making it the first OTC CGM available to pediatric patients. And PwC's latest report confirms what billing departments already knew: AI is very good at finding new ways to charge more.
Top Stories
Lead Story
Story 01
Thena Capital has completed the final close of its inaugural fund at £45 million, marking a significant milestone for the venture capital firm and reinforcing its focus on supporting early-stage medical technology companies in the UK. The fund is anchored by the British Business Bank's Enterprise Capital Funds program, making Thena Capital the first all-female, general-partner-led fund backed by the initiative.
Thena Capital was founded by Pamela Walker Geddes, Esther Reynal de St Michel Richardot, and Tatum Getty around a clear thesis: the UK produces world-class medical technology innovation but lacks sufficient specialist capital with commercial expertise and transatlantic connections to help companies scale globally. The firm has assembled a limited partner base composed of healthcare executives, pharmaceutical leaders, specialist investors, operators, and family offices. More than half of the fund's LPs are women.
During its first year of investing, Thena backed five companies: Plexiaa, Salient Bio, Sanome, Heim, and Zonova. Fund I is expected to invest in approximately 25 early-stage companies focused on digital health platforms and accelerated medical devices, with initial investments ranging from £500,000 to £1 million at the seed stage.
Why It Matters
The UK MedTech funding gap is well-documented but rarely addressed with institutional-grade capital. Thena Capital's £45 million fund, anchored by the British Business Bank, is a signal that the gap is being taken seriously by the institutions that matter. The all-female GP structure is notable but secondary to the real story: a firm with genuine specialist depth and transatlantic ambition is now backed by a credible anchor LP and has a clear deployment target.
The five companies backed in year one share a consistent pattern: validated technology, strong clinical need, clear commercialization pathway, and international ambition. That discipline matters. A fund that deploys £500K to £1M at seed across 25 companies is building a portfolio that requires follow-on capital to reach scale. The transatlantic positioning is the mechanism for that follow-on.
Watch for Thena's portfolio companies as they move through Series A. The firm has the commercial expertise and LP network to open doors that most UK-focused funds cannot. This is a fund to track.
Venture Capital
Digital Health
Medical Devices
Story 02
Star51 Capital has announced the first close of its inaugural fund for early- and growth-stage medtech companies. Abbott and Mayo Clinic led the fund's first closing, with participation from senior medtech executives, physicians, and life science professionals. Star51 invests across interventional therapies, diagnostics, monitoring, and digital health worldwide.
Founding Managing Partners Adam Rosenwach and Tal Wenderow lead the fund. Wenderow founded Corindus Vascular Robotics and led it through its $1.1 billion acquisition by Siemens Healthineers. Rosenwach previously held senior operating and finance roles across medtech incubators and high-growth startups. Raymond W. Cohen, co-founder of Axonics and an experienced medtech exit leader, serves as operating partner.
Star51 is structured as an "ecosystem fund," combining strategic capital with deep operator networks to accelerate portfolio companies through critical inflection milestones. Wenderow said: "Medtech is at an inflection point. Technology advancements and AI are reshaping how devices are designed, delivered, and personalized. The companies that will help define the next era of Medtech are being built today. We believe the time to support them with capital and the right operational expertise is now."
Why It Matters
Abbott and Mayo Clinic co-leading a medtech fund's first close is not a trivial signal. These are organizations with deep clinical and commercial intelligence about what medtech categories are generating real outcomes. Their willingness to commit capital as anchor LPs tells you something about the deal flow and deal quality Star51 is positioned to access.
The ecosystem fund structure is the differentiator. Traditional venture funds provide capital and board seats. Star51's model layers on operator networks: Cohen's Axonics experience, Wenderow's Siemens exit track record, and the clinical insight network from Mayo Clinic. That combination gives portfolio companies access to commercial relationships and regulatory experience that most seed and Series A investors cannot provide.
Rosenwach's framing is accurate: "an ecosystem built by operators, for operators." The medtech capital formation stack is maturing. Star51 is part of that maturation, and the Abbott/Mayo Clinic co-lead is the market's vote of confidence in the thesis.
Venture Capital
Interventional
Digital Health
Story 03
The FDA has cleared Dexcom's Stelo glucose biosensor system for use in children two years of age and older who do not use insulin, making it the first over-the-counter continuous glucose monitor (CGM) cleared for pediatric prediabetic and diabetic patients. Stelo was initially cleared for individuals age 18 and above in March 2024. No other OTC CGM is currently available in the pediatric population in the US.
Stelo is a wearable sensor that pairs with an app to continuously measure, record, analyse, and display glucose values, with each sensor lasting up to 15 days. The FDA highlighted the clearance as an example of its use of real-world evidence (RWE) to support regulatory decision-making. Dexcom worked with the FDA evaluating a combination of previous clinical study data from pediatric and adult diabetes patients, along with real-world data on current iCGM use among both groups, to understand expected device performance in pediatric users.
Dexcom held 44.7% of the US CGM market share in 2025, second only to Abbott (48.5%). The global CGM market is projected to reach $15.69 billion in 2035 per GlobalData analysis. Michelle Tarver, director at FDA's Center for Devices and Radiological Health (CDRH), said: "Children deserve access to the best tools available to manage their health. This clearance supports the safe and effective use of medical devices where children live, learn, and play."
Why It Matters
The pediatric OTC CGM market is new territory, and Dexcom just claimed it. Abbott's Lingo and Libre CGM remain 18+ only, leaving Dexcom as the only OTC option for parents of children with prediabetes or Type 2 diabetes who don't use insulin. That's a meaningful expansion of the addressable market without a direct competitor in that space.
The RWE pathway for pediatric clearance is the regulatory story. The FDA used real-world performance data from the 18+ population to support the pediatric clearance without requiring a full separate clinical trial. That's an efficiency gain that speaks to how the agency's approach to pediatric device approvals is evolving. More device companies will follow this pathway.
At 44.7% US market share, Dexcom is already the dominant OTC player. Adding a pediatric indication without a peer competitor in that space is a pure market expansion. The 15-day wear, app-pairing model translates cleanly to pediatric use cases where continuous monitoring gives parents and caregivers actionable data they currently lack.
FDA
AI / Digital
Diabetes
Story 04
A new 60-page PwC report finds that AI is one of five drivers pushing US healthcare costs up to 9% in 2027, matching the highest rate since 2010-11. The primary mechanism: AI note-taking tools are documenting more diagnoses and medical complications that rushed human clinicians would have coded under a single broad label. Those extra details justify higher severity billing codes, increasing reimbursement even when the actual care delivered is unchanged.
One Blue Cross Blue Shield analysis found that the billing code for acute posthemorrhagic anemia in new mothers jumped from 4% to 12.3% of maternity admissions between 2022 and 2025. Actual blood transfusion rates barely moved. An audit of the hospital system with the steepest rise in this code found fewer than 20% of the cases actually met the clinical criteria for the diagnosis. BCBS estimates coding intensity added $22 million to maternity spending at the hospitals studied over three years.
The report acknowledges that AI is the top-ranked new cost pressure but not the largest overall driver of increases. Labor and supply costs still account for more of the total. And AI tools could eventually drive costs down by automating administrative work or catching diagnoses earlier. "Companies will take AI and say, 'How can I use this to further my self-interest?'" one health insurance executive told Axios.
Why It Matters
PwC's report confirms a dynamic that was observable before it was documented. AI note-taking tools in hospitals generate revenue by capturing clinical complexity that physicians either miss or don't document in real time. The billing uplift is real. The clinical value is debatable: fewer than 20% of the escalated diagnoses in the BCBS audit met actual clinical criteria for the code used.
This is not a medtech story in the device sense, but it is a medtech-relevant story. The hospitals using AI billing tools are the same systems buying medical devices. The economic incentives that drive AI billing adoption will shape purchasing decisions, contract structures, and the vendor relationships that medtech companies depend on. Understanding which hospital systems are deploying AI billing tools, and at what scale, is relevant competitive intelligence.
The long-term counterargument is real: Morgan Stanley projects AI could save healthcare $305 billion annually by 2050 through administrative automation and earlier diagnosis. But the near-term reality is that the billing optimization use case is deployed and generating revenue now. The savings case is still theoretical. This is a MedTech Minute coverage theme for Q3 and Q4 2026.
AI
Cost / Reimbursement
Digital Health
The Signal
Four stories, four different angles on the same underlying theme: MedTech capital formation and the regulatory and commercial pathways that create defensible positions. Thena Capital's £45 million fund is the UK funding gap finally getting addressed with institutional backing. Star51's inaugural close with Abbott and Mayo Clinic as anchor LPs is the US medtech ecosystem fund model gaining credibility. Dexcom's pediatric Stelo clearance is a pure market expansion in a space where it has no OTC peer. And PwC's AI billing analysis is a reminder that the economic incentives shaping hospital behavior are a first-order input for anyone selling into health systems.
The thread connecting all four: the infrastructure for building, scaling, and selling MedTech is getting more sophisticated. Capital formation is more specialized. Regulatory pathways are adapting (RWE for pediatric clearances). Commercial incentives are being stress-tested by AI. The companies that understand these dynamics will have an edge over those that focus only on the technology.
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $476.30 | ▲ 0.4% |
| SYK | Stryker | $307.80 | ▲ 0.6% |
| BDX | Becton Dickinson | $240.10 | ▲ 0.3% |
| DHR | Danaher | $113.50 | ▲ 0.6% |
| JNJ | Johnson & Johnson | $228.40 | ▲ 0.3% |
| DXCM ★ | Dexcom | $72.10 | ▲ 1.8% |
| EW | Edwards Lifesciences | $83.90 | ▲ 0.5% |
| BSX | Boston Scientific | $80.80 | ▲ 0.5% |
| MDT | Medtronic | $80.20 | ▲ 0.4% |
| GEHC | GE HealthCare | $66.50 | ▲ 0.6% |
★ Biggest Mover: Dexcom (DXCM) gained 1.8% following FDA clearance of Stelo as the first over-the-counter CGM for children age 2 and older, expanding the addressable market into pediatric prediabetes and diabetes without a direct OTC competitor in that space. Sorted by stock price, highest to lowest. Prices reflect approximate close, week of June 18, 2026. For illustrative purposes only.
⏳ That's your 5-minute briefing. Below: extras if you want to go deeper.
Fun Fact
💡 Fun Fact: The UK MedTech Funding Gap
Thena Capital's £45 million fund is the first all-female GP-led fund backed by the British Business Bank's Enterprise Capital Funds program. The UK produces world-class medical technology innovation but has historically lacked the specialist capital with commercial expertise and transatlantic connections to help companies scale globally. Thena's fund targets approximately 25 early-stage companies at seed stage with initial investments of £500K to £1M.
Trivia
MedTech Trivia
What specific mechanism did the FDA use to clear Dexcom Stelo for pediatric patients without requiring a new clinical trial, and why is this regulatory approach significant for future pediatric device approvals?
If you're building, hiring, or investing in MedTech, reply and tell me what you're seeing. I read every response.
